(Q37369958)

20 August 2017

1 reference

title

The application of high-dose interleukin-2 for metastatic renal cell carcinoma (English)

1 reference

20 August 2017

0 references

David F McDermott

1

1 reference

20 August 2017

16 January 2009

1 reference

20 August 2017

1 reference

20 August 2017

26 Suppl 1

1 reference

20 August 2017

13-17

1 reference

https://scigraph.springernature.com/pub.10.1007/s12032-008-9152-1

20 August 2017

0 references

cites work

Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12032-008-9152-1

Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis

21 January 2018

1 reference

12 December 2020

Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

1 reference

12 December 2020

Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response

1 reference

12 December 2020

Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials

1 reference

12 December 2020

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

12 December 2020

Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells

1 reference

12 December 2020

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

12 December 2020

Erythropoietin production. A potential marker for interleukin-2/interferon-responsive tumors

1 reference

12 December 2020

Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma

1 reference

12 December 2020

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer

1 reference

12 December 2020

Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.

1 reference

12 December 2020

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

12 December 2020

Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma.

1 reference

12 December 2020

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

12 December 2020

Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup

1 reference

12 December 2020

Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy

1 reference

12 December 2020

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

12 December 2020

Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group

1 reference

12 December 2020

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 reference

12 December 2020

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

12 December 2020

Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy

1 reference

12 December 2020

Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer

1 reference

12 December 2020

Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma

1 reference

12 December 2020

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

1 reference

12 December 2020

Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous alpha-interferon

1 reference

12 December 2020

10.1007/S12032-008-9152-1

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19148594